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Abstract (word count 248, max. 250)
Aims: The TNM classification system is used for prognostication purposes and to guide patient 
management. However, in colorectal cancer (CRC), additional markers are needed to stratify 
prognostic subgroups. From large bodies of research, two promising markers have emerged: 
Tumour budding and T-cell host response (CD3, CD8 and CD45RO infiltrates). However, 
attempts to combine these two parameters have been sparse. The aim of this study was to perform 
an assessment of potential protagonists that could be used in a combined score (Budding/T-cell 
Score, BTS). 
Methods and Results: This descriptive, retrospective study was performed on a multi-punch tissue 
microarray containing material from 345 patients with Stage I-IV CRC. Areas from tumour centre, A
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front and microenvironment were stained for Pancytokeratin/CD3, Pancytokeratin/CD8 and 
Pancytokeratin/CD45RO. Tumour buds were scored manually and T-cell infiltrates digitally using 
open-source software (QuPath). Tumour buds, T-cell counts and combined BTS were associated 
with clinico-pathological features and overall survival (OS).
A higher combined BTS score (Buds/CD8, tumour centre) performed better than budding or 
CD8/CD3 alone in predicting nodal metastases (p<0.0001, OR 1.466, 95%CI: 1.115-1.928). Only 
higher BTS (Buds/CD3) was significantly associated with poorer OS on multivariate analysis (p= 
0.012, HR 1.218, 95%CI: 1.044-1.419).
Conclusions: Although CD8+/CD3+ T-cells are predictive of tumour biology in CRC, we found a 
combined BTS to be stronger in predicting survival and certain features with high clinical 
relevance, such as nodal metastases, in comparison to budding or T-cells alone. Further studies 
combining T-cell infiltrates and tumour budding are necessary to optimize risk assessment of 
CRC.
Keywords: Tumour budding, colorectal cancer, host response, Immunoscore
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Introduction
The TNM staging system remains the main classification system used to determine prognosis and 
therapy in cancer patients. However, as the TNM classification in colorectal cancer (CRC) is quite 
heterogeneous in different stages 1, 2, additional parameters have been proposed to complement 
this system. Here, the concepts of tumour budding 3, 4 and Immunoscore 5, 6 have emerged as 
particularly promising candidates.  
Many studies have investigated tumour budding, defined as single tumour cells and small clusters 
of four or less tumour cells as a robust predictor of lymph node and distant metastasis, relapse and 
poorer outcome 7-9. These strong associations can be exploited in specific clinical scenarios 10.  A 
recent proposal of standardized assessment of tumour budding (according to the International 
Tumor Budding Consensus Conference 2016, ITBCC) 10 has led to its integration in the CRC 
checklist of the College of American Pathologists 11, and widespread reporting of this feature can 
be expected in the future. From a biological perspective, tumour budding may represent the 
morphological correlate of epithelial-mesenchymal-transition as a key step in progression and 
invasion of solid cancers 12-14 . 
Immune cells have also been intensively studied and are now recognized as an essential 
component of the tumour microenvironment 15. Indeed, certain tumours, most notably 
microsatellite-instable (MSI-high) CRC, are associated with a dense T-cell lymphocytic infiltrate, 
less tumour budding and better prognosis 16-18. Meanwhile, many works have led to the 
recognition of three lymphocyte markers: CD3+, CD8+ and CD45R0+ 19-21 and the concept of 
Immunoscore 22, 6.  A validation study demonstrating Immunoscore to be a reliable predictor of 
recurrence risk has recently been published 5.
To date, most investigations of tumour budding and T-cell infiltrates in CRC have been 
independent from each other. Introducing the concept of the ‘attacker-defender model’, a previous 
study examining a combined CD8+T-cell/tumour budding index demonstrated superior prognostic 
information than either marker alone 23. Nevertheless, a systematic analysis of potential 
protagonists of the attacker-defender model has not yet been conducted. The aim of this study was 
to assess tumour budding in relationship to the T-cell infiltrate focusing on CD3+, CD8+ and 
CD45R0+ subpopulations (Budding/T-cell Score, BTS) in different tumour areas and to determine 
which elements lead to the best correlation with aggressive tumour biology and patient outcome. A
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Materials and Methods
Patient cohort 
A retrospective collective of 345 primary colorectal cancer patients treated by resection at the 
University Hospital of Bern between 2002 and 2014 was used for this study. Cases were re-
reviewed (A.L. and H.D.) based on the TNM 7th edition (review performed prior to the publication 
of the 8th edition). Assessed features (Table 1) include histological subtype, tumour location, pT, 
pN, pM and TNM stage (defined as pT, pN and either pM or cM at the time of diagnosis), grade, 
lymphatic invasion, venous invasion, perineural invasion, Klintrup-Mäkinen score 24, tumour 
budding scored by the ITBCC recommendations 10 and by immunohistochemical pankeratin stains 
(‘overall tumour budding, OTB’) 25. Importantly, tumour budding had previously been assessed by 
both of these methods on whole tissue slides on these cases and was significantly associated with 
poorer survival 25, 26. Status of mismatch repair (MMR) proteins was assessed by 
immunohistochemistry of MLH1, MSH2, PMS2 and MSH6 as previously described 27 and 
classified as mismatch-repair deficient (nuclear loss of at least one marker) and proficient. 
Information on therapy and overall survival were obtained for all patients (mean and median 
follow-up time, 47.8 and 40.7 months, respectively). Information on synchronous or metachronous 
distant metastases was available for 324 patients (cM0/cM1 in Table 1). No patients received 
preoperative therapy. The use of patient material was approved by the ethics commission of the 
canton of Bern (KEK 2017-01803, October 24, 2017).
Next Generation Tissue Microarray construction
This study was performed on a tissue microarray using the next generation tissue microarray 
(ngTMA®) approach 28. Annotations made from areas containing tumour tissue were selected in 
the highest budding areas. For each patient, three punches from different histological regions were 
investigated: tumour centre, tumour front, and tumour microenvironment (areas at the tumor/host 
interface containing tumor buds as well as non-tumoural cells) defined as previously described 29 
(n=9 spots per patient, core diameter 0.6mm for all tumour areas).
Double immunohistochemistry for CD8/pankeratin, CD3/ pankeratin and CD45R0/ 
pankeratinA
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Three double immunostains were performed, namely the pankeratin cocktail AE1/AE3 to 
highlight tumour cells and CD8, CD3 or CD45RO, respectively. Double immunostains ngTMA 
blocks containing cores from tumour centre, front and microenvironment using the BOND-RX 
Automated System (Leica Microsystems GmbH, Newcastle, United Kingdom). ngTMA blocks 
were cut at 4 µm, deparaffinised and pre-treated with the Epitope Retrieval Solution 2 (Citrate-
buffer pH 8.8) at 100 C° for 20min. After wash steps, peroxidase blocking was carried out for 4 
min using the Bond Polymer Refine Detection Kit DC9800 (Leica Microsystems GmbH). Tissues 
were again washed, then incubated with primary antibody against AE1/AE3 with the dilution 
1:200 (DakoCytomation, Glostrup, Denmark) for 30min. Subsequently, tissues were incubated 
with polymer for 15 min and then with DAB-Chromogen for 10min (Bond Polymer AP Red 
Detection Kit DS9305, Leica Microsystems GmbH). After washing, incubation was carried out 
with anti-CD8 (DakoCytomation, Glostrup, Denmark), anti-CD3 (Abcam, Cambridge) and anti-
CD45RO (Abcam, Cambridge) with the dilutions CD8 1 :100, CD3 1 :400, CD45RO 1 :5000  for 
30 min (reduced to 15 min in optimizing the CD45RO protocol) followed by application of AEC-
substrate for 10 min and counterstaining with haematoxylin for 5 min. 
Evaluation of tumour budding cells and T-cell infiltrates on digital slides 
Analysis of tumour buds and T-cell infiltrates on the double immunostains was performed on 
scanned slides (P250, 3DHistech, Budapest, Hungary) using the open source software QuPath 30. 
As algorithms for reliable automated digital assessment of tumour budding are still under 
development, buds were scored manually using an online tool ‘Scorenado’ especially developed 
for TMA scoring 31, on dearrayed spots.  Tumour budding was defined as an isolated tumour cell 
or a cluster of four or less tumour cells irrespective of location. Punches containing only stroma 
(no tumour) were excluded from further evaluation and therefore have no BTS scores. 
For assessment of T-cell infiltrates with QuPath, automatically detected TMA spots underwent 
manual quality control and correction. Tissue areas were detected automatically and manual 
quality control was performed to remove artefacts. Stroma areas were defined by subtracting 
tumour areas from their parent tissue areas. Cell detection was performed within stroma areas and 
the detected cells subsequently classified as ‘T-cells’ and ‘other’ using a threshold classifier based 
on eosin staining. The procedure of digital assessment of T-cell infiltrates is depicted in Fig. 1. All A
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scripts used for image analysis in QuPath are available under 
https://github.com/TranslationalResearchUnit/CRC-BTS. 
Calculation of Budding/T-cell scores (BTS) 
To calculate the density of T-cells, the digital count was divided by the corresponding stroma area. 
Tumour bud cell density was calculated by dividing the number of buds counted on Scorenado 
divided by the corresponding stroma area. The Budding/T-cell score (BTS) was defined as the 
number of tumour buds divided by the number of lymphocytes. The BTS was first calculated for 
each tissue spot individually. The BTS on a patient level was calculated for each combination of 
tumour area type and T-cell type as the mean of all BTSs on tissue spot level of the corresponding 
combination. As division by zero is not possible, the count of all tumour buds (numerator) and 
immune cells (denominator) was increased by +1.
Statistical analysis
The association of the BTS scores with clinico-pathological features was obtained using the 
Wilcoxon rank sum test for binary features, the Kruskal-Wallis test for ordinal features, and the 
Spearman test for continuous features. All p-values (Supplementary file S2) were two-sided and 
considered significant when p < 0.05. These analyses were carried out using the SciPy library 
(version 1.1.0) in Python 3.5.1. For survival analysis a univariate Cox regression and a 
multivariate Cox regression (including T-stage, N-stage, cM stage and postoperative therapy) was 
performed, using the lifelines library (0.13.0) for Python 3.5.1. Hazard ratios (HR) and 95%CI 
were obtained to determine the effect of each feature. 
Results
T-cell/budding count alone versus BTS and clinico-pathological features
The distribution of all scores in different tumour areas is shown in Supplementary File S1. 
Associations between T-cell infiltrates, tumour budding scores and a combined BTS score are 
depicted in Fig. 3, with exact p-values in Supplementary File S2. Comparing the T-cell infiltrates, 
the number of significant statistical associations with clinico-pathological features for CD3 and 
CD8 were markedly higher than CD45RO both as single parameters and in a combined BTS score. 
Focusing on CD3 and CD8, infiltrates assessed in the tumour centre stood out with high A
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associations with lower pT-stage (p<0.001, both), lower pN-stage (p=0.0085 and p<0.001, 
respectively), cM-stage (p<0.001 and p=0.0088), higher pTNM stage (p<0.001, both), absence of 
lymphatic invasion (p=0.0024 and p=0.0003) and blood vessel invasion (p=0.0106 and p=0.009), 
higher KM-Score (p<0.001, both), and lower tumour budding counts as assessed by the ITBCC 
method (p=0.0005 and p=0.0042).  
Tumour budding showed consistent significant associations in virtually all areas (centre, front, 
tumour microenvironment) with aggressive tumour biology, with higher pT-stage (p=0.0125, 
p=0.0418 and p=0.0062), pN-stage (p=0.0002, p=0.0005 and p<0.001), TNM-stage (p=0.0011, 
p=0.0025 and p<0.001), lymphatic invasion, blood vessel invasion and perineural invasion. 
Importantly, correlations between tumour budding assessed on the TMA punches and by ITBCC 
and OTB methods were both highly significant (p<0.001, all areas) 
For CD3 and CD8 BTS from the tumour centre, higher scores were associated with higher pT-
stage (p= p<0.001, both), higher pN-stage (p=0.004 and p<0.001, cM-stage (p=0.0007 and 
p=0.0015), pTNM-stage (p<0.001, both), lymphatic invasion (p<0.001, both), venous invasion 
(p=0.001, p=0.006), perineural invasion (p=0.0032 and p=0.0003), lower Klintrup-Mäkinen score 
(p=0.0042 and p=0.0002), OTB (p=0.0162 and p=0.0162)  and ITBCC scores (p<0.001, both).    
BTS vs. immune cell/budding count alone as a predictor of lymph node metastasis and 
survival 
In the context of clinically relevant endpoints (lymph node metastasis and overall survival), 
associations with T-cell infiltrates, tumour buds and BTS scores were assessed.  
On univariate analysis, higher CD8 infiltrates in the tumour centre were associated with better OS 
(p=0.0002), followed by CD3 in the tumour centre (p=0.0016). The BTS showed centre and TME 
CD3 BTS as well as centre CD8 BTS to be associated with poorer survival (p=0.0437, 0.0266, and 
0,0214 respectively).  Budding on the TMA spots as a sole parameter was not significant for OS in 
this cohort.  However, in multivariate analysis including T-stage, N-stage, cM stage and 
postoperative therapy, only higher centre CD3 BTS scores were significantly associated with 
poorer OS (p= 0.012, HR 1.218, 95%CI: 1.044-1.419). 
For predicting nodal metastases, only centre CD8 BTS scores were significant for predicting nodal 
metastases (p<0.0001, OR 1.466, 95%CI: 1.115-1.928). A
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Discussion 
This study is the first analysis to explicitly examine T-cell populations and tumour budding cells 
in colorectal cancer as a combined Budding/T-cell Score in different tumour areas. Here, although 
T-cell infiltrates and tumour budding were both strongly associated with clinico-pathological 
features, a combined score was superior to either marker alone, especially for predicting nodal 
metastases and survival. 
T-cell infiltrates in solid cancers have been the focus of many studies, and the recently validated 
Immunoscore has been demonstrated to provide valuable information on recurrence risk in non-
metastatic colon cancer 5.  However, Immunoscore may not completely reflect the biology of the 
tumour itself.  Here, we study how the ‘attacker-defender model’ might enhance the estimation of 
tumour biology compared to tumour budding or T-cell infiltrates as separate parameters. For 
instance, it would be conceivable that additional quantification of T-cell infiltrates could 
counteract the effect of tumour budding. This may prove useful in clinical scenarios where tumour 
budding can be implemented to guide patient management, such as estimating the risk of nodal 
metastases in endoscopically resected pT1 CRC 9, 32 and in stage II CRC 33, 34 10. 
Our group has previously demonstrated superior prediction of survival when using a combined 
index of tumour buds and T-cells. For instance, a CD8/tumour budding index was shown to 
increase the prognostic effect of tumour budding 23. Similarly, a combined assessment of CD8, 
FOXP3 and CD68 positive immune cells and tumour buds was also described to improve 
stratification of patients into prognostic risk groups 35. Even histomorphological assessment of 
tumour-infiltrating lymphocytes and tumour buds may increase the impact of tumour budding 
alone, as recently suggested 36. 
Taking into account insights on the T-cell landscape of CRC, we focus on several well-established 
T-cell protagonists (CD3, CD8 and CD45RO) in different areas of the tumour.  Interestingly, the 
most robust parameters in our assessment are CD3 and CD8 BTS scores originating from the 
tumour centre.  Although traditionally assessed at the tumour front 10, tumour budding within the 
tumour centre (intratumoural budding, ITB) is well-documented in the literature and strongly A
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correlated with budding seen at the tumour front 25, 37, 38.  The fact that budding can be seen in the 
centre of a tumour strongly supports that dissemination does not occur only in regions rigidly 
defined as ‘tumour front’ and ‘tumour microenvironment’39. Such areas of infiltrative tumour 
growth may also be highly convoluted and therefore also captured in regions corresponding to our 
‘tumour centre’ punches. Finally, technical aspects such as levelling through TMA cores may have 
additionally contributed to a higher consistency of scores derived from the tumour centre. 
Nonetheless, practical implications of this finding include potential application of the BTS score in 
pre-operative rectal biopsies, where additional information on tumour spread may influence the 
decision to administer neoadjuvant therapy 40, 41.   
 
From the T-cell counts, CD3 and CD8 counts were superior compared to CD45RO, which was 
also reflected in the BTS scores.  Though regulatory T-cells have been implicated as an important 
player in the immune cell infiltrate in CRC 6, 42, 43, inconsistencies and background positivity in 
immunohistochemical stains have previously been reported 6, 44, leading to the exclusion of 
CD45RO from Immunoscore 6. The diminished performance of CD45RO-based scores here is 
most likely also due to this phenomenon despite efforts to improve the quality of the immunostain, 
indicating that this marker may not be suitable for quantification performed by visual scoring or 
digital assessment. 
Our proposal of the BTS aims to reflect the ‘attacker’ and ‘defender’ as aggressive and protective 
forces in CRC. However, further studies are required to validate whether these opposite markers 
can indeed be united in a combined score. Although our study was performed on a multi-punch 
TMA including several punches from different tumour areas, due to the nature of this approach 
evaluated tissue originated from pre-selected areas. This would account for the lack of association 
between tumour buds scored on the TMA spots and survival, as tumour budding assessed on 
whole tissue slides from this collective was associated with poorer overall survival (by both OTB 
and ITBCC methods25, 26). Validation studies may be performed on whole tissue slides to optimize 
the selection of regions most suitable for BTS assessment. 
One of the novel aspects of this study is the assessment of T-cell infiltrates using open-source 
software. The implementation of such methods will likely be able to replace cumbersome manual 
assessment in the near future.   As digital scoring of tumour buds can also be anticipated, a fully A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
automated BTS-algorithm could be developed.  The BTS is not meant to replace tumour budding 
and Immunoscore as robust biomarkers in CRC, but to further underline and reflect their 
importance alongside other pathological parameters. Potential applications of the BTS include 
clinical scenarios where a precise estimation of tumour biology is required to guide patient 
management, such as in endoscopically resected pT1 tumours, stage II CRC and pre-operative 
rectal biopsies. Our results warrant further study and development of the BTS in CRC. 
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Tables
Table 1: Patient characteristics (n=345) 
Feature Freq N (%) or
Mean, median
Gender (n=345) Male
Female
209 (60.6)
136 (39.4)
Patient age (n=345) Mean, median 69.5, 70.9
Histological subtype (n=326) Adenocarcinoma
Mucinous
Other
283 (86.8)
37 (11.3)
6 (1.8)
Tumour location (n=320) Left-sided
Right-sided
Rectum
142 (44.4)
118 (36.9)
60 (18.8)
pT (n=342) pT1-2 59 (17.3)
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pT3-4 283 (82.2)
pN (n=342) pN0
pN1-2
160 (46.7)
182 (53.3)
Number of examined lymph nodes 
(n=338)
Mean, median 24.2, 21.0
Distant metastases (n=324) cM0
cM1
238 (73.5)
86 (26.5)
p/cTNM-Stage (n=339) Stage I
Stage II
Stage III
Stage IV
37 (10.9)
126 (37.2)
120 (35.4)
56 (16.5)
Tumour grade (n=332) G1-2
G3
259 (78.0)
73 (22.0)
% expanding tumour border 
(n=302)
Mean, median 45.9, 50.0
Number of buds ITBCC (n=106) Mean, median 8.1, 6.0
OTB mean (n=186) Mean, median 11.2, 8.0
Lymphatic invasion (n=310) L0
L1
98 (31.6)
212 (68.4)
Venous invasion (n=293) V0
V1-2
141 (48.1)
152 (51.9)
Perineural invasion (n=300) Pn0
Pn1
247 (80.7)
59 (19.3)
Klintrup-Mäkinen (n=305) 0
1
2
3
25 (8.2)
129 (42.3)
119 (39.0)
32 (10.5)
Postoperative therapy (n= 284) No
Yes
196 (69.0)
88 (31.0)
MMR status (n=190) Proficient
Deficient
164 (86.3)
26 (13.7)
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Abbreviations: ITBCC: International Tumor Budding Consensus Conference; OTB : Overall tumor 
budding; MMR : Mismatch repair
Figure Legends
Fig. 1: Low (A-C) and high (D-F) BTS scores for each double immunostain. A+D: 
CD3/Pankeratin, B+E: CD8/Pankeratin, C+F: CD45RO/Pankeratin (images all taken between 15-
20x). Selected tumour buds marked by asterisks, selected T-cells marked by arrows (A-F). The 
CD45RO/Pankeratin immunostain shows extensive non-specific staining which was still present 
after protocol optimization.
Fig. 2: Digital analysis of TMA spots (0.6 mm in diameter) and assessment of T-cell infiltrates. a) 
Double immunostain (CD8(red)/Pankeratin(brown)) before and b) after tissue separation. ‘Stroma’ 
was defined as the non-epithelial, non-T-cell area (nuclei annotated in green). 
Fig. 3: Plot of associations between T-cell infiltrates, tumour buds and Budding/T-cell scores with 
clinico-pathological features and overall survival. Increased numbers of T-cells are associated with A
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more favourable tumour biology, whereas increased numbers of tumour buds and higher 
Budding/T-cell scores are associated with aggressive tumour biology. Abbreviations: TME: 
tumour microenviroment, BTS: Budding/T-cell scores, KM-Score: Klintrup-Mäkinen score, OTB: 
overall tumour budding, ITBCC: International tumour budding consensus conference, OS: overall 
survival   
Supplementary Files: 
S1: Distribution of T-cell and tumour bud counts and BTS scores in different tumour areas
S2: Depiction of Fig. 3 with exact p-values
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